A genetic test to predict anti-tnf drug response

David Gibson; AJ Bjourson; Cathy McGeough; Martin A Crockard; John Lamont

A genetic test to predict anti-tnf drug response

David Gibson (Inventor)
, AJ Bjourson (Inventor)
, Cathy McGeough (Inventor)
, Martin A Crockard (Inventor)
, John Lamont (Inventor)

Research output: Patent

Abstract

This invention relates to predicting a subjects responsiveness to biologic therapy of rheumatoid arthritis. The invention provides a method for predicting responsiveness to anti-tumour necrosis factor therapy of rheumatoid arthritis in a subject, the method comprising the steps of:(a) Providing a biological sample;(b) detecting the presence, absence, or quantitative level of a first marker or an expression product thereof, wherein the first marker is at the HLA DRB1 gene;(c) detecting the presence, absence, or quantitative level of a second marker, or an expression product thereof, wherein the second marker is at the CD226 gene;(d) correlating the presence, absence, or quantitative level of the first marker and the presence, absence, or quantitative level of the second marker; to the predicted responsiveness to anti-tumour necrosis factor therapy of rheumatoid arthritis in the subject.

Original language	English
Patent number	US2023/0193364 A1
Priority date	22/05/20
Filing date	21/05/21
Publication status	Published (in print/issue) - 22 Jun 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Rheumatoid Arthritis
Biologics
Anti-TNF-α
Personalised Medicine
Companion Diagnostics
Genomics

Access to Document

https://patents.google.com/patent/US20230193364A1/enLicence: CC BY

Cite this

@misc{44cabb8857db4f4a876eb4f0f920f955,

title = "A genetic test to predict anti-tnf drug response",

abstract = "This invention relates to predicting a subjects responsiveness to biologic therapy of rheumatoid arthritis. The invention provides a method for predicting responsiveness to anti-tumour necrosis factor therapy of rheumatoid arthritis in a subject, the method comprising the steps of:(a) Providing a biological sample;(b) detecting the presence, absence, or quantitative level of a first marker or an expression product thereof, wherein the first marker is at the HLA DRB1 gene;(c) detecting the presence, absence, or quantitative level of a second marker, or an expression product thereof, wherein the second marker is at the CD226 gene;(d) correlating the presence, absence, or quantitative level of the first marker and the presence, absence, or quantitative level of the second marker; to the predicted responsiveness to anti-tumour necrosis factor therapy of rheumatoid arthritis in the subject.",

keywords = "Rheumatoid Arthritis, Biologics, Anti-TNF-α, Personalised Medicine, Companion Diagnostics, Genomics",

author = "David Gibson and AJ Bjourson and Cathy McGeough and Crockard, \{Martin A\} and John Lamont",

year = "2023",

month = jun,

day = "22",

language = "English",

type = "Patent",

note = "US2023/0193364 A1",

}

TY - PAT

T1 - A genetic test to predict anti-tnf drug response

AU - Gibson, David

AU - Bjourson, AJ

AU - McGeough, Cathy

AU - Crockard, Martin A

AU - Lamont, John

PY - 2023/6/22

Y1 - 2023/6/22

N2 - This invention relates to predicting a subjects responsiveness to biologic therapy of rheumatoid arthritis. The invention provides a method for predicting responsiveness to anti-tumour necrosis factor therapy of rheumatoid arthritis in a subject, the method comprising the steps of:(a) Providing a biological sample;(b) detecting the presence, absence, or quantitative level of a first marker or an expression product thereof, wherein the first marker is at the HLA DRB1 gene;(c) detecting the presence, absence, or quantitative level of a second marker, or an expression product thereof, wherein the second marker is at the CD226 gene;(d) correlating the presence, absence, or quantitative level of the first marker and the presence, absence, or quantitative level of the second marker; to the predicted responsiveness to anti-tumour necrosis factor therapy of rheumatoid arthritis in the subject.

AB - This invention relates to predicting a subjects responsiveness to biologic therapy of rheumatoid arthritis. The invention provides a method for predicting responsiveness to anti-tumour necrosis factor therapy of rheumatoid arthritis in a subject, the method comprising the steps of:(a) Providing a biological sample;(b) detecting the presence, absence, or quantitative level of a first marker or an expression product thereof, wherein the first marker is at the HLA DRB1 gene;(c) detecting the presence, absence, or quantitative level of a second marker, or an expression product thereof, wherein the second marker is at the CD226 gene;(d) correlating the presence, absence, or quantitative level of the first marker and the presence, absence, or quantitative level of the second marker; to the predicted responsiveness to anti-tumour necrosis factor therapy of rheumatoid arthritis in the subject.

KW - Rheumatoid Arthritis

KW - Biologics

KW - Anti-TNF-α

KW - Personalised Medicine

KW - Companion Diagnostics

KW - Genomics

M3 - Patent

M1 - US2023/0193364 A1

Y2 - 2021/05/21

ER -

A genetic test to predict anti-tnf drug response

Abstract

UN SDGs

Keywords

Access to Document

Fingerprint

Cite this